Protection of reproduction function in women with Hodgkin's disease in the course of polychemotherapy
Ignashina, E.V.; Rasstrigin, N.A.; Margolin, O.V.; Pivnik, A.V.; Shilin, D.E.
Terapevticheskii Arkhiv 71(10): 29-32
1999
ISSN/ISBN: 0040-3660 PMID: 10612170 Document Number: 507192
Aim. To evaluate efficiency of estrogen-gestagen treatment for protection of the ovaries during polychemotherapy. Materials and methods. Ultrasonography of the pelvic organs, radioimmunoassay of LH, FSH, prolactin, E2, testosterone were performed in 95 women of child-bearing age with different stages of Hodgkin's disease. Results. Cytostatic therapy of Hodgkin's disease had ovariotoxic effects and led to amenorrhea in 83% of the examinees. Regular estrogen-gestagen treatment protected ovaries in 86% of the patients. Conclusion. It is recommended for women to take estrogen-gestagen drugs to protect ovaries during polychemotherapy of Hodgkin's disease.